Soliqua 100/33 (lixisenatide/insulin glargine) / Zealand Pharma, Sanofi - LARVOL DELTA

Choice of Insulin Coformulations: Biphasic Insulin Versus Insulin-GlP1RA. (PubMed, J Pak Med Assoc) - "A comprehensive evaluation,including severity and style of glycaemia, clinical presentation, comorbidities, complications, and culinary preference, allows efficient choice of insulin formulation. This framework helps in initiation,intensification and interchange of injectable therapy,in an apt, and ept, manner."

Journal

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations? (PubMed, Diabetes Obes Metab) - "Basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are available in two fixed-ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide. An HbA1c goal of <6.5% is less likely to be appropriate for patients requiring basal insulin, which is included in the FRCs. Ideal candidates for FRCs are those (1) taking oral antihyperglycemic medications only with an HbA1c <10% and <2% away from goal, (2) those on basal insulin and above HbA1c goal, (3) those unwilling or unable to initiate or manage multiple daily injections (i.e., basal-bolus insulin therapy) and (4) those tolerating a GLP-1 RA who require basal insulin to achieve glycemic goals."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of Time of Injection Comparing iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes—Exploratory Analysis of the SoliD Study (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Enhanced Glycemic Control and Weight Benefits of Insulin Glargine plus lixisenatide vs. Insulin Glargine in Type 2 Diabetes (ADA 2025) - "Available on Friday, June 20, 2025 at 10:30am CDT."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Efficacy and Safety of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) by Baseline Age, Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) Use, and BMI—Post Hoc Analysis of Soli-CGM (ADA 2025) - "Available on Friday, June 20, 2025 at 10:30am CDT."

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study (ADA 2025) - "Available on Friday, June 20, 2025 at 10:30am CDT."

Clinical • Retrospective data • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Switching to Iglarlixi from Premix Insulin Regimen in Patients with T2DM—Real-World Experience (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Real-world • Real-world evidence • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycemic Outcomes When Switching to iGlarLixi from Premixed Insulin (PI) in People with Type 2 Diabetes (T2D) by iGlarLixi Pen Subgroups—Post Hoc Analysis of Soli-SWITCH (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Early Glycemic Improvement When Switching to iGlarLixi from Premixed Insulins (PI) in Adults with Type 2 Diabetes (T2D)—A Post Hoc Analysis of Soli-SWITCH (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies. (PubMed, Diabetes Obes Metab) - "Once-daily iGlarLixi was associated with superior blood glucose control and body weight benefit compared with IDegAsp in insulin-experienced populations with T2D in non-Asian RCTs."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico. (PubMed, Diabetes Obes Metab) - "iGlarLixi demonstrated a consistent safety profile aligned with findings from previous randomised controlled trials. The most common ADRs were gastrointestinal disorders that were generally tolerable. Over 50% of participants treated with iGlarLixi achieved their glycaemic targets."

Journal • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

INSULIN THERAPY DE-INTENSIFICATION WITH IGLARLIXI IN PEOPLE WITH TYPE 2 DIABETES: THE IDEAL RANDOMISED CONTROLLED TRIAL (ATTD 2025) - "The proportion of study visits at which hypoglycemia was reported was lower in the iGlarLixi vs MDI group (5.5% vs 9.6%, p=0.029). No differences in FPG and PPG were observed.Conclusions Insulin therapy de-intensification from MDI into iGlarLixi is an efficient and safe treatment option for PwT2D that provides comparable glycaemic control with the benefits of reduction of BW, TDD, number of insulin injections and lower proportion of visits as which hypoglycaemia was reported."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

INSULIN TREATMENT SIMPLIFICATION WITH IGLARLIXI IN RELATIVELY WELL-CONTROLLED PATIENTS WITH TYPE 2 DIABETES (ATTD 2025) - "The percentage of patients reporting at least one episode of hypoglycemia at BV, V1, and V2 was 52.5%, 30.5%, and 22%. The mean dose of iGlarlixi at V1 and V2 was 21.8±8.3 and 22.1±8.7 dose steps.Conclusions Replacing complex insulin regimens with iGlarLixi in relatively well-controlled patients with T2D results in similar or better glycemic control with with lower insulin doses, fewer daily injections, less hypoglycemia and a favorable effect on body weight."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

REAL-WORLD EFFECTIVENESS AND SAFETY OF IGLARLIXI IN ADULTS WITH TYPE 2 DIABETES IN LATAM REGION: A SUB-ANALYSIS OF SUCCESS STUDY (ATTD 2025) - "Conclusions This sub-analysis demonstrated that effectiveness and safety of iGlarLixi observed in LATAM population are consistent with overall global study. Once-daily iGlarLixi injection may be an efficacious and safe therapeutic option for PwT2D in LATAM region."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

REAL-WORLD EFFECTIVENESS AND SAFETY OF IGLARLIXI IN ADULTS WITH TYPE 2 DIABETES IN GULF COUNTRIES: A SUB-ANALYSIS OF SUCCESS STUDY (ATTD 2025) - "Conclusions This sub-analysis demonstrated effectiveness and safety of iGlarLixi in Gulf participants which are consistent with those observed in overall study population. Once daily iGlarLixi injection may be an efficacious and safe treatment option for adults with T2D in Gulf countries."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFECT OF IGLARLIXI IN TIME IN RANGE USING FLASH CGM IN A MEXICAN COHORT OF ADULTS WITH SUBOPTIMAL CONTROLLED TYPE 2 DIABETES (ATTD 2025) - "Initial median (IQR) A1c was 9 (2)% and after 3 months 7(2)%.Conclusions The treatment with iGlarLixi increased by 28% the TIR at 12 weeks. There was a reduction in the percentage of time in hypoglycemia and a decrease of A1c of 2%."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

INSULIN THERAPY DE-INTENSIFICATION WITH IGLARLIXI (IDEAL) RANDOMISED CONTROLLED TRIAL: PATIENT-REPORTED OUTCOMES (ATTD 2025) - "No changes were observed with the ADDQoL and HABS questionnaires. Conclusions Insulin therapy de-intensification from MDI into iGlarLixi in PwT2D led to significant improvement in patient satisfaction with diabetes treatment as evidenced by the data from DTSQs/DTSQc questionnaires."

Clinical • Patient reported outcomes • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

INSULIN THERAPY DE-INTENSIFICATION WITH IGLARLIXI (IDEAL) RANDOMISED CONTROLLED TRIAL – CGM RELATED OUTCOMES (ATTD 2025) - "Median (IQR) %TBR (< 3.9 mmol/L) remained unchanged in iGlarLixi group (0 [0 – 1] vs 1 [0 – 2], p=0.337) and MDI group (0.5 [0 – 2] vs 1 [0 – 3.75], p=0.147). Conclusions Insulin therapy de-intensification from MDI into iGlarLixi in PwT2D showed improvement in several CGM metrics without increase in hypoglycaemia."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

DERIVED TIME-IN-RANGE (DTIR) IN PEOPLE WITH TYPE 2 DIABETES (PWT2D) SWITCHING TO IGLARLIXI FROM PREMIXED INSULIN: A POST-HOC ANALYSIS OF THE SOLI-SWITCH STUDY (ATTD 2025) - P4 | "Additionally, 54.8% (46.6, 62.7) participants achieved triple target of dTIR >70%, dTAR <25%, and dTBR <4%. Conclusions In PWT2D switching from premixed-insulin, iGlarLixi improved dTIR and reduced dTAR, without increasing dTBR, making it an effective once-daily option to simplify insulin therapy without increasing hypoglycemia risk."

Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

IMPROVED PATIENT- AND PHYSICIAN-REPORTED OUTCOMES WITH IGLARLIXI WHEN SWITCHING FROM PREMIXED INSULIN IN PEOPLE WITH TYPE 2 DIABETES (T2D): THE SOLI-SWITCH STUDY (ATTD 2025) - P4 | "GTEE scores (mean; 95% CI) increased from Week 12 to Week 24 for both patients (2.6; −0.2, 5.5) and physicians (3.6; 0.9, 6.4) ( Table ). Conclusions Switching from PI to iGlarLixi was associated with improvements in patient- and physician-reported outcomes, particularly in reducing treatment burden and enhancing treatment effectiveness, following 24 weeks of treatment."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study. (PubMed, Diabetes Obes Metab) - P4 | "iGlarLixi initiation was associated with improved glycaemic control, without body weight gain or increased hypoglycaemia over 24 weeks."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study. (PubMed, Adv Ther) - "Consistent with clinical trials, this post-marketing database study observed that newly prescribed iGlarLixi has a low risk of serious hypoglycaemia or hyperglycaemia in Japanese people with T2D, irrespective of prior antidiabetic drug treatment."

Journal • P4 data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies. (PubMed, Diabetes Obes Metab) - "In Asian people with T2D suboptimally controlled on OADs or BI, iGlarLixi provided comprehensive earlier glycaemic control than Gla-100."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials. (PubMed, Endocrine) - "Compared with insulin glargine, iGlarLixi is superior in reducing blood glucose levels and facilitating weight loss. Nevertheless, its administration is also linked to a heightened occurrence of gastrointestinal and adverse events."

Journal • Retrospective data • Diabetes • Gastrointestinal Disorder • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. (PubMed, Diabetes Obes Metab) - "In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RA, 16 weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus